Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart  by Halestrap, Andrew P. et al.
Elucidating the molecular mechanism of the permeability transition pore
and its role in reperfusion injury of the heart
Andrew P. Halestrap a;*, Paul M. Kerr b, Sabzali Javadov c, K.-Y. Wood¢eld a
a Department of Biochemistry, University of Bristol, Bristol BS8 1TD, UK
b Bristol Heart Institute, University of Bristol, Bristol Royal In¢rmary, Upper Maudlin Street, Bristol BS2 8HW, UK
c Azerbaijan Medical University, Bakykhanov Str., Baku, Azerbaijan
Received 19 December 1997; revised 6 February 1998; accepted 12 March 1998
Abstract
First, we present a summary of the evidence for our model of the molecular mechanism of the permeability transition
(MPT). Our proposal is that the MPT occurs as a result of the binding of mitochondrial cyclophilin (CyP-D) to the adenine
nucleotide translocase (ANT) in the inner mitochondrial membrane. This binding is enhanced by thiol modification of the
ANT caused by oxidative stress or other thiol reagents. CyP-D binding enhances the ability of the ANT to undergo a
conformational change triggered by Ca2. Binding of ADP or ATP to a matrix site of the ANT antagonises this effect of
Ca2 ; modification of other ANT thiol groups inhibits ADP binding and sensitises the MPT to [Ca2]. Increased membrane
potential changes the ANT conformation to enhance ATP binding and hence inhibit the MPT. Our most recent data shows
that a fusion protein of CyP-D and glutathione-S-transferase immobilised to Sepharose specifically binds the ANT from
Triton-solubilised inner mitochondrial membranes in a cyclosporin A (CsA) sensitive manner. Second we summarise the
evidence for the MPT being a major factor in the transition from reversible to irreversible injury during reperfusion of a heart
following a period of ischaemia. We describe how in the perfused heart [3H]deoxyglucose entrapment within mitochondria
can be used to measure the opening of MPT pore in situ. During ischaemia pore opening does not occur, but significant
opening does occur during reperfusion, and recovery of the heart is dependent on subsequent pore closure. Pore opening is
inhibited by the presence in the perfusion medium of pyruvate and the anaesthetic propofol which both protect the heart
from reperfusion injury. Third we discuss how the MPT may be involved in determining whether cell death occurs by necrosis
(extensive pore opening and ATP depletion) or apoptosis (transient pore opening with maintenance of ATP). ß 1998
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1. Introduction
When mitochondria are exposed to supraphysio-
logical matrix concentrations of calcium, they be-
come non-selectively permeable to small molecules
(6 1500 Da). This causes uncoupling, loss of low
molecular weight components from the matrix and
swelling, a phenomenon that has been recognised for
several decades and is often referred to as the mito-
chondrial permeability transition (MPT). The sensi-
tivity of the MPT to [Ca2] is greatly increased by
oxidative stress, adenine nucleotide depletion, ele-
vated phosphate concentrations, low membrane po-
tential and agents such as carboxyatractyloside
(CAT) that stabilise the ‘c’ conformation of the ad-
enine nucleotide translocase (ANT). In contrast, pro-
tection is a¡orded by low pH, high membrane po-
tential, cyclosporin A (CsA), and agents that stabilise
the ‘m’ conformation of the ANT (see [1^4]). We
begin this article by providing a brief summary of
our current understanding of the molecular mecha-
nism of the MPT that may account for these obser-
vations. We then move on to consider the role of the
MPT in causing the irreversible damage to a heart
that occurs when it is reperfused following a period
of ischaemia, a phenomenon known as reperfusion
injury [2^4]. Cardiac surgeons must avoid such re-
perfusion injury if the outcome of open heart surgery
is to be successful. We end the article by showing
how this may be achieved as a result of our increas-
ing understanding of the molecular mechanism of the
MPT.
2. The molecular mechanism of the MPT
The size pro¢le of solutes that can enter the mito-
chondrial matrix following the MPT implies the
Ca2-dependent formation of a non-speci¢c channel
in the inner mitochondrial membrane, as does the
immediate reversal of the MPT by chelation of
Ca2 with EGTA [5,6]. However, despite strong evi-
dence to the contrary, for many years it was argued
that the MPT was induced by activation of mito-
chondrial phospholipase A2 leading to a non-speci¢c
increase in the permeability of the inner membrane
phospholipid bilayer [7]. This view became untenable
when it was demonstrated that the MPT can be spe-
ci¢cally and totally inhibited by sub-micromolar con-
centrations of the immunosuppressive drug cyclo-
sporin A (CsA) without any e¡ect on
phospholipase A2 activity [8^10]. Our own studies
on the mechanism of the MPT were initiated by
this observation. We have endeavoured to simplify
the number of variables that may contribute to the
regulation of the MPT and have usually used de-
energised mitochondria, more recently in the pres-
ence of the calcium ionophore A23187. This ensures
that mitochondrial membrane potential and matrix
[Ca2] are held constant, and thus factors in£uencing
the MPT cannot be doing so indirectly through these
parameters.
2.1. The role of mitochondrial cyclophilin in the
mitochondrial permeability transition
The immunosuppressive action of CsA is mediated
by a complex between cytosolic cyclophilin (CyP-A)
and CsA that inhibits calcineurin, a Ca-sensitive pro-
tein phosphatase [11^13]. This led us to investigate
whether a mitochondrial CyP was responsible for the
e¡ects of CsA on the MPT. Matrix CyP was assayed
by its CsA-sensitive peptidyl-prolyl cis-trans isomer-
ase (PPIase) activity and the K0:5 values of CsA ana-
logues for inhibition of this enzyme were found to be
very similar to their K0:5 values for inhibition of the
MPT [10,14]. More recent work from this and other
laboratories has con¢rmed these observations [15,16].
Furthermore, the number of binding sites required
for 100% inhibition of the MPT corresponded to
the concentration of PPIase within the matrix (about
50 pmol per mg protein) [10,16]. We were able to
purify and N-terminal sequence the CsA-sensitive
mitochondrial PPIase [17] and so con¢rm that it
was a member of the cyclophylin (CyP) family,
most probably identical to the product of the human
CyP-3 gene product [18]. This is a nuclear encoded
protein with a mitochondrial targeting presequence
that is cleaved after translocation of the protein
into the matrix. It is now more usually termed
CyP-D [12,13]. Cleavage occurs at one of two points
leading to mature proteins of about 17.6 kDa (minor
product) and 18.6 kDa (major product). Crompton
and colleagues have also puri¢ed and sequenced a
mitochondrial CyP which they found associated
with the inner mitochondrial membrane in a manner
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suggestive of it being involved in the MPT [19,20].
This also proved to be CyP-D, but its larger size (21
kDa) suggests that it may represent the protein be-
fore cleavage of the signal sequence. We have cloned
and sequenced the cDNA for rat mitochondrial CyP
(accession number U68544). With the exception of
the extreme N-terminal residue, the sequence corre-
sponds exactly to the N-terminus sequence of the
puri¢ed protein, thus con¢rming that the matrix
PPIase in rat mitochondria is indeed the equivalent
of human CyP-3 (CyP-D). Northern blots demon-
strate that mRNA for CyP-D is present in rat
muscle, heart, liver, kidney and brain and is of iden-
tical size (1.5 kb) in all tissues. This makes it unlikely
that there are di¡erently spliced tissue-speci¢c iso-
forms [21].
2.2. CyP-D is recruited to the inner mitochondrial
membrane under conditions that enhance the
MPT
The PPIase activity of CyP-D suggested to us that
its role in the mechanism of the MPT might be to
interact with an integral membrane protein and cause
a change in its conformation which, when triggered
by Ca2, would induce pore opening. In view of the
in£uence of the ANT conformation on this process
[1^3] we suggested that the integral membrane pro-
tein might be the ANT [10,14]. A proline residue
(Pro61) on a putative matrix loop of the transporter
was proposed as the binding site since an adjacent
lysine shows conformation speci¢c labeling [10,14].
One mechanism by which the MPT might be sensi-
tised to [Ca2] would be through an increased bind-
ing of CyP to its target protein. We provided evi-
dence in support of this by demonstrating that
oxidative stress induced with t-butyl hydroperoxide
(TBH), glutathione depletion induced by diamide
treatment or modi¢cation of vicinal thiols by phenyl-
arsine oxide (PheArs) all increased CyP binding to
the inner mitochondrial membrane [22,23]. These re-
agents all increase the sensitivity of pore opening to
[Ca2]. In order to show this e¡ect the mitochondrial
membranes had to be prepared in iso-osmotic KSCN
medium to stabilise the complex between CyP and its
membrane target protein. Stabilisation could also be
achieved by the addition of low concentrations of
guanidinium hydrochloride, implying that it is the
chaotropic properties of KSCN that are responsible
for its stabilising e¡ects [23]. This suggests that the
CyP forms a complex with the target protein, induc-
ing a conformational change that exposes more of
the protein surface to the aqueous medium. Such
an e¡ect might be predicted for the formation of a
channel. Another factor that enhances both CyP
binding and MPT opening in response to [Ca2] is
an increase in matrix volume [23]. In all cases, bind-
ing of CyP was almost totally prevented by CsA. In
contrast, we have been unable to show signi¢cant
e¡ects on CyP binding of several other known mod-
ulators of the MPT including matrix [Ca2], [ADP],
pH or membrane potential. This implies that these
e¡ectors are acting at another site that regulates the
sensitivity of the MPT towards [Ca2] [23,24]. How-
ever, Bernardi and colleagues have demonstrated an
inhibitory e¡ect of low pH on CyP-D binding to sub-
mitochondrial particles [15]. The e¡ect was blocked
by the histidine reagent diethylpyrocarbonate which
also blocks the inhibitory e¡ect of pH on the MPT
[25]. These experiments were performed in low ionic
strength media where a large number of other matrix
proteins also remained bound to the membrane at
low pH, and thus it is possible that the e¡ect of
pH was on non-speci¢c binding of CyP-D to charged
groups on the phospholipids or membrane proteins.
Crompton and colleagues [19,20] used similar condi-
tions when labelling the membrane bound CyP-D
with photoactivatable CsA derivatives. Their data
suggested that Ca2 might enhance and ADP dimin-
ish CyP binding under such conditions.
Despite the evidence described above, there is now
a body of data to suggest that CyP binding may not
be essential for pore opening, but may rather sensi-
tise the process to [Ca2]. Thus Novgorodov et al.
[26] and Crompton and Andreeva [27], using di¡er-
ent techniques, have shown that at high matrix
[Ca2] inhibition of pore opening by CsA is over-
come. We have con¢rmed this in both heart mito-
chondria [14] and liver mitochondria [22^24]. Yet
under the same conditions, CsA is able to prevent
almost totally the binding of CyP-D to the inner
mitochondrial membrane [22,24]. In addition, studies
on the megachannel of patched clamped mitochon-
dria, which it has been suggested may represent the
MPT pore, have shown that an inhibitory e¡ect of
CsA is overcome at higher [Ca2] [28,29]. However,
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recent data has cast doubt on whether the megachan-
nel and the MPT pore are the same molecular entity
[30].
2.3. The role of the adenine nucleotide translocase
in the mitochondrial permeability transition
An involvement of the ANT in pore opening was
¢rst proposed by Hunter and Haworth [5] and more
convincing evidence provided by LeQuoc and Le-
Quoc [31] and ourselves [10,24]. The evidence was
based largely around the observation that any re-
agent such as CAT that stabilised the ‘c’ conforma-
tion of the ANT, stimulated the MPT, whilst any
reagent such as bongkrekic acid (BKA) that stabi-
lised the ‘m’ conformation of the ANT, inhibited
the MPT. Furthermore, matrix ADP is an important
modulator of pore opening that acts by decreasing
the sensitivity of the calcium trigger site to [Ca2].
There are two ADP binding sites with Ki values of
about 1 and 25 WM. The high a⁄nity site is blocked
by the inhibitor CAT and therefore thought to be
associated with the ANT [5,6,24,26,32]. We have
tested the ability of a range of other nucleotides to
inhibit the MPT, and found that only ATP and de-
oxy-ADP inhibit with K0:5 values 500 and 20 times
greater than ADP, respectively. This correlates with
their a⁄nity for the matrix binding site of the ANT
[24]. Adenine nucleotide binding is antagonised by
oxidative stress induced by TBH or diamide and
also by thiol reagents such as PheArs, a powerful
activator of the MPT [24,33]. PheArs has the greatest
e¡ect of the reagents tested, raising the K0:5 for ADP
inhibition of the MPT to s 500 WM [24]. We have
shown that this e¡ect is accompanied by covalent
modi¢cation of the ANT [24] which may explain
why PheArs is a more potent stimulus of the MPT
than diamide or TBH, and yet has a smaller e¡ect on
CyP binding [23].
Bernardi and colleagues have provided strong evi-
dence that the MPT is voltage-regulated, being acti-
vated as the membrane potential becomes less nega-
tive [34^39]. We have suggested that the membrane
potential is sensed by the ANT itself through an
e¡ect on adenine nucleotide binding. This is not un-
likely, since the ANT is an electrogenic carrier, trans-
porting ATP43 in exchange for ADP33 with a mech-
anism that may well involve a potential driven
conformational change that alters the a⁄nity of the
adenine nucleotides on either side of the membrane
[40^42]. In support of this hypothesis, we have dem-
onstrated that in mitochondria depleted of adenine
nucleotides by pyrophosphate treatment, not only is
the MPT much more sensitive to [Ca2], but it is also
no longer voltage sensitive [16,24]. Oxidative stress
shifts the voltage dependence of the MPT, allowing
the pore to open at more negative potentials. Two
distinct thiol groups have been implicated in this
e¡ect [37,43,44]. One is sensitive to oxidation of glu-
tathione, for example by TBH or diamide, and is
protected by both monobromobimane and N-ethyl-
maleimide. The other responds to the redox state of
matrix NAD(P), and is protected by N-ethylmale-
imide but not monobromobimane. It is the latter
site that accounts for the well documented stimula-
tory e¡ect of oxidation of matrix NADH on the
MPT perhaps through the mediation of thioredoxin
or lipoamide [45,46]. The ANT is known to have
three cysteine residues that show di¡erential reactiv-
ity to various thiol reagents and oxidising agents in a
conformation dependent manner [47^49]. These cys-
teines may well represent the thiol groups that regu-
late both CyP-D binding and the inhibitory e¡ects of
ADP and membrane potential on the MPT [24].
Although a role for the ANT in the MPT is now
generally accepted (see [1^3]), there has been debate
as to whether this protein may itself form the pore or
rather be a regulatory component. Recently it has
been shown that the puri¢ed and reconstituted
ANT can form Ca2-dependent channels resembling
the permeability transition pore [50] which provides
strong support for the proposed mechanism. What is
lacking is direct evidence for an interaction of CyP-D
with the ANT and we have directed a great deal of
e¡ort towards providing such a demonstration. At-
tempts at chemical cross-linking of the CyP-D to the
ANT have so far been unsuccessful. As an alterna-
tive approach we have overexpressed CyP-D as a
glutathione-S-transferase fusion protein in E. coli
and have immobilised this on Sepharose-glutathione
resin in order to investigate ANT binding directly
(unpublished data of K. Wood¢eld and A.P. Hale-
strap). We found that when fully solubilised in 3%
Triton X-100, the ANT does not bind to the GST-
CyP, but this may not be surprising since the con-
formation of the ANT in detergent is unlikely to
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re£ect that in the membrane. However, when inner
mitochondrial membranes (IMMs) were resuspended
in 0.5% Triton X-100 (partial solubilisation) and
then incubated with the immobilised GST-CyP-D, a
range of proteins bound to the fusion protein in a
CsA sensitive manner. This was demonstrated by
SDS-PAGE of the GSH-eluted proteins and visual-
isation using silver staining as shown in Fig. 1a. One
of the proteins that bound in a CsA-sensitive manner
was the ANT as revealed by parallel Western blot-
ting with anti-ANT antibodies. In contrast, Western
blotting with anti-porin antibodies demonstrated no
porin binding under the same conditions (Fig. 1a).
These data alone do not allow us to conclude that
speci¢c binding of the ANT to GST-CyP-D is occur-
ring since, in addition to the ANT, other proteins
may remain in the partially-solubilised IMM fraction
and be responsible for the binding of membranes
containing ANT. However, the data of Fig. 1b pro-
vide very strong evidence that the interaction is
through the ANT rather than through another asso-
ciated protein. Thus pre-treatment of the IMMs with
CAT before their partial solubilisation in 0.5% Tri-
ton X-100 almost totally abolished ANT binding to
the GST-CyP-D, whilst having no appreciable e¡ect
on total protein binding. BKA had a similar but less
pronounced e¡ect. These data demonstrate that
binding of the ANT to the column was conforma-
tion-dependent, suggesting that a direct interaction
between the ANT and the CyP-D was responsible
for removing the ANT from the partially solubilised
membranes.
2.4. The locus of action of di¡erent modulators
of the MPT
In Table 1 we summarise our current thinking on
how di¡erent modulators of the MPT exert their
e¡ects. We suggest that the ANT provides a common
locus for these e¡ects. Binding of matrix adenine
nucleotides to the ANT inhibits pore formation by
decreasing the a⁄nity of the trigger site for [Ca2].
Adenine nucleotide binding is antagonised by thiol
reagents, the ‘c’ conformation of the carrier and
membrane depolarisation which therefore sensitise
the MPT to [Ca2]. We have suggested that the thiol
group Cys159 may be involved in these e¡ects and
may represent one of the vicinal thiols to which
PheArs binds [24]. The ‘m’ conformation and in-
creased membrane potential enhance nucleotide
binding and inhibit the pore. These e¡ectors are all
without e¡ect on CyP-D recruitment to the mem-
brane. In contrast, chaotropic agents and increased
matrix volume sensitise the MPT to [Ca2] by in-
creasing CyP-D binding, an e¡ect that thiol reagents
Fig. 1. Binding of the adenine nucleotide translocase to a GST-
CyP-D a⁄nity matrix. Rat liver mitochondrial inner mem-
branes (IMM), prepared according to [164], were solubilised at
1 mg protein/ml in KPi bu¡er (20 mM KPi, pH 7.4, 0.1 mM
EDTA, 0.5% (w/v) Triton X-100) containing where indicated
1 mM ADP, 1 WM CsA or cyclosporin H (CsH), 10 WM CAT
or 20 WM BKA. Aliquots (1 ml) were incubated for 30 min at
25‡C with immobilised GST-CyP-D which was synthesised by
binding 0.25 mg GST-CyP-D (fusion protein between GST and
CyP-D overexpressed in E. coli) to 0.2 ml glutathione-Sephar-
ose resin (Pharmacia). Where the e¡ect of CsA or CsH on
binding was to be studied, the GST-CyP-D was preincubated
with 25 WM CsA or CsH prior to addition of IMMs, in order
to ensure saturation of CyP-D binding sites with CsA. In (a)
one aliquot of immobilised GST-CyP-D was incubated in the
absence of IMMs. Following incubation, the Sepharose was
sedimented by centrifugation, washed 5 times with 1 ml KPi
bu¡er and then bound protein released by incubation with 0.6
ml bu¡er containing 75 mM Tris, pH 8.0, 300 mM NaCl, 0.5%
Triton X-100 and 10 mM GSH. The eluted proteins were sepa-
rated by SDS-PAGE (12% acrylamide) and either protein bands
stained with silver (top) or subjected to Western blotting (bot-
tom) with either anti-ANT (a and b) or anti-porin antibodies (a
only). The far left track of each Western blot (labelled IMM
only) shows IMMs not subjected to binding on the GST-CyP-
D resin but separated by SDS-PAGE to con¢rm the presence
of ANT and porin in the IMM fraction. The antibodies were
kind gifts from Dr Gerard Brandolin and Dr Vito de Pinto, re-
spectively. Data shown are unpublished results of K.-Y. Wood-
¢eld and A.P. Halestrap.
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and oxidative stress also induce, perhaps through
modi¢cation of Cys56 [24]. This facilitates the tran-
sition of the ANT into its open channel state. Low
pH and Mg2 are suggested to compete directly with
Ca2 at the trigger site. Tri£uoperazine is a potent
inhibitor of the MPT under energised but not de-
energised conditions [24]. It was originally thought
to act indirectly through inhibition of phospholipase
A2, preventing the accumulation of free fatty acids
which stimulate the MPT, probably through interac-
tion with the ANT. However, inhibition occurs even
without changes in free fatty acid accumulation and
is now thought to be mediated by an e¡ect on sur-
face membrane charge that changes the voltage sen-
sitivity of the MPT [51].
2.5. Other possible components of the MPT pore
The question arises as to whether there are other
components of the pore, and it seems probable that
the answer is yes. We have found that sub-mitochon-
drial particles (SMPs) maintain a succinate driven
membrane potential that is not dissipated in the pres-
ence of 1 mM [Ca2] whether or not 10 WM puri¢ed
CyP-D is added (unpublished data of A.P. Hale-
strap). This demonstrates that pore opening is not
occurring under such conditions and implies that a
matrix component, lost on preparation of the SMPs,
is required for operation of the MPT. One possibility
for this protein would be a calcium binding protein
that provides the calcium trigger site for the MPT.
Others have suggested an involvement of the outer
membrane porin and benzodiazepine receptor [3,52]
since these components have been reported to copu-
rify with the ANT as a complex under some condi-
tions [53]. Attractive though this proposal is, espe-
cially in the light of the recent suggestion that the
MPT is involved in the release of cytochrome c dur-
ing apoptosis (see below), the evidence for it is lack-
ing. First, ligands of the mitochondrial benzodiaze-
pine receptor are without e¡ect on the MPT [24].
Second, the MPT can be observed in mitoplasts
from which the outer membrane has been largely
removed by digitonin treatment and exhibits identi-
cal properties to the MPT in normal mitochondria
(A.P. Halestrap, unpublished data). Third, the data
of Fig. 1a show that unlike the ANT, porin does not
bind to the GST-CyP-D a⁄nity matrix.
3. The role of the mitochondrial permeability
transition in the ischaemic/reperfused heart
The impermeability of the mitochondrial inner
membrane to all but a few selected metabolites and
ions is essential for the maintenance of the mem-
brane potential and pH gradient that drive ATP syn-
thesis during oxidative phosphorylation. When this
permeability barrier is disrupted by opening of the
MPT pore, mitochondria become uncoupled and the
proton-translocating ATPase actively hydrolyses
rather than synthesises ATP. If this were to occur
in a cell, ATP concentrations could not be main-
tained even by glycolysis. Unless the pore can close
Table 1
Proposed sites of action of known modulators of the mitochondrial permeability transition
E¡ect via change in cyclophilin-D binding E¡ect via change in nucleotide binding Direct e¡ect on Ca2 binding
Activatory
Thiol reagents (e.g. diamide PheArs) Thiol reagents (e.g. Diamide PheArs) High pH
Oxidative stress (e.g. TBH) Oxidative stress (e.g. TBH)
Increased matrix volume ‘C’ conformation of ANT
Chaotropic agents
Inhibitory
CsA Membrane potential Low pH
Membrane surface charge (e.g. tri£uoperazine) Mg2
‘M’ conformation of ANT
The site of action of the di¡erent modulators is discussed in the text. Note that both CyP binding and ADP binding exert their e¡ects
through changes in the sensitivity of the MPT to [Ca2].
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again, the cell would be destined to die, since damage
to cellular components caused by hypoxia and oxi-
dative stress can only be repaired if ATP is available,
but will continue unabated in its absence [2,54].
Eventually, the permeability barrier of the plasma
membrane will be compromised through phospholip-
ase A2 action, and leakage of cell contents and dis-
ruption of ion gradients will then ensure cell death.
Thus the MPT provides a mechanism by which ne-
crotic cell death can be initiated, and there is increas-
ing evidence that this is indeed the case as will be
described below.
In the ischaemic heart, cells endeavour to maintain
their ATP levels through glycolysis. This leads to an
accumulation of lactic acid, a decrease in intracellu-
lar pH and a consequent inhibition of contraction
and glycolysis [55,56]. The Na/H antiporter en-
deavours to correct the decrease in pHi, loading the
cell with Na which requires the Na/K ATPase to
drive it out [57^59]. If there is insu⁄cient ATP to
allow this, the Na accumulates and also prevents
Ca2 from being pumped out of the cell on the
Na/Ca2 antiporter; the process may actually be
reversed and allow additional Ca2 entry [59,60].
Fig. 2. Scheme summarising factors involved in reperfusion injury of the heart. The solid lines represent events that occur during the
ischaemic phase and the dashed lines the subsequent e¡ects of reperfusion. Details are given in the text.
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During ischaemia, calcium may also enter the mito-
chondria by reversal of the Na/Ca2 antiporter [61],
but upon reperfusion Ca2 is rapidly taken up into
the mitochondria by means of the uniporter [62,63].
The sudden in£ux of oxygen into a hypoxic cell in-
duces the formation of oxygen free radicals through
an interaction of oxygen with ubisemiquinone which
is formed during hypoxia as a result of respiratory
chain inhibition [54,64,65]. Additional oxygen free
radicals are produced through the operation of xan-
thine oxidase [66]. This enzyme is activated during
hypoxia and is presented with high concentrations of
xanthine produced by the purine degradation that
occurs during hypoxia [67]. The combination of ox-
idative stress and high [Ca2] provides the ideal con-
ditions for the MPT, especially in the presence of
elevated cellular phosphate concentrations and de-
pleted adenine nucleotide levels, both of which occur
during ischaemia [2,4,54,68]. Furthermore, during
the reperfusion phase the intracellular pH rapidly
returns to pre-ischaemic values through the opera-
tion of the Na/H antiporter, lactic acid e¥ux on
the monocarboxylate transporter (MCT) and bicar-
bonate dependent mechanisms [58]. Thus the inhib-
itory e¡ect of low pH on the MPT [69,70] is re-
moved, allowing the other stimulators of the
process to exert their full e¡ect. The sequence of
events described above is summarised in Fig. 2. It
is well established that the reperfusion phase follow-
ing a prolonged period of ischaemia is more damag-
ing than the ischaemia itself, and activation of the
MPT provides an explanation for this. Indeed mor-
phological studies con¢rm mitochondria become
swollen and amorphous under such conditions [2,68].
4. Direct measurement of pore opening during
reperfusion of the ischaemic heart
In order to establish directly that the MPT occurs
in intact tissues under pathological conditions it is
necessary to measure mitochondrial pore opening
in situ. In isolated hepatocytes subjected to oxidative
stress, this has been achieved using laser scanning
confocal microscopy with the intracellular green £u-
orescent dye, calcein, in combination with the mito-
chondrial membrane potential sensitive red £uores-
cent dye tetramethylrhodamine (TMRM) [71,72].
The calcein only enters the mitochondria when the
MPT pore opens, whilst TMRM leaves the mito-
chondria under these conditions. This technique has
been used to show that mitochondria undergo the
MPT during necrotic cell death induced by oxidative
stress [71,72]. CsA, especially in the presence of tri-
£uoperazine, inhibits the MPT and protects cells
from death. In isolated heart cells measurement of
hyper-contracture and mitochondrial membrane po-
tential with £uorescent dyes have been used as an
indirect indicator of pore opening during re-oxygen-
ation following anoxia and once again protection by
CsA has been observed [73,74]. There was also a
correlation between mitochondrial [Ca2] content
and subsequent cell death [62,63].
These techniques for measuring the MPT cannot
easily be applied to the perfused heart and we have
devised an alternative procedure that relies on the
impermeability of the inner mitochondrial membrane
to 2-deoxyglucose-6-phosphate [16]. The principle be-
hind this technique is summarised in Fig. 3. Hearts
are perfused in Langendor¡ recirculating mode with
[3H]-2-deoxyglucose [DOG] which enters the heart
on the glucose carrier and is then phosphorylated
to DOG-6-phosphate. This is not further metabolised
and is trapped within the cell. It would not be ex-
Fig. 3. The principle behind using 2-DOG to measure the open-
ing of MPT pores in the perfused heart.
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pected to enter mitochondria unless the pore opens.
After washing out extracellular [3H]-DOG, hearts are
subjected to various periods of ischaemia and reper-
fusion as outlined above, and then mitochondria pre-
pared rapidly and assayed for [3H]-DOG and citrate
synthase (an indicator of mitochondrial recovery).
From the [3H]-DOG content of the mitochondria
and a small sample of total heart homogenate an
estimation of pore opening is possible. As shown in
Fig. 4, mitochondria prepared immediately after the
ischaemic period showed no increase in DOG con-
tent, but those prepared following a period of reper-
fusion showed a signi¢cant increase [16]. Pore open-
ing is maximal after 5 min of reperfusion [75] and
this corresponds to the period of time over which the
intracellular pH returns to pre-ischaemic values [58].
Thus our data suggest that a profound opening of
the mitochondrial pore occurs only during the reper-
fusion phase, consistent with the predictions made
above. It has been argued that pore opening is not
a primary cause of cell injury but rather a secondary
phenomenon that occurs following other critical
damage to the myocyte, such as breakdown of the
plasma membrane permeability barrier [76]. How-
ever, if the latter were to occur, DOG would be
lost from the cell before it could enter the mitochon-
dria and thus no increase in mitochondrial DOG
would be measured.
5. Measurement of MPT reversal in hearts that
recover during reperfusion
Recovery of heart function during reperfusion can
be measured using pressure transducers to monitor
beat, left ventricular developed pressure (LVDP), end
diastolic pressure (EDP) and aortic pressure. In ad-
dition adenine nucleotide concentrations can be de-
termined in hearts freeze-clamped after the ischaemic
period or after reperfusion [77]. Reperfusion after
short periods of ischaemia leads to total recovery
of LVDP and ATP/ADP ratio, yet using the DOG
technique, we have demonstrated that even under
these conditions mitochondria undergo the MPT
[16,75,77]. This suggests that the opening of the mi-
tochondrial pores must be transient, rapid resealing
allowing total recovery of mitochondrial function
and heart performance. Unfortunately, when the
MPT reverses, closure of the mitochondrial pores
means that DOG remains trapped inside the mito-
chondria and the reversal is not detected. Detection
requires a modi¢cation of the DOG technique, in
which hearts are loaded with [3H]-DOG during re-
Fig. 5. The e¡ects of 10 mM pyruvate on the opening and sub-
sequent closure of MPT pores during reperfusion of hearts fol-
lowing global ischaemia. Mitochondrial DOG entrapment was
measured in either (a) hearts pre-loaded with [3H]-DOG before
40 min global ischaemia and then reperfusion for 20 min or (b)
hearts subjected to 40 min global ischaemia and 20 min reper-
fusion before post-loading with [3H]-DOG. Where indicated 10
mM pyruvate was present 10 min before ischaemia and during
reperfusion. Data are taken from [113].
Fig. 4. The time dependence of MPT pore opening in hearts re-
perfused following 30 min global ischaemia. Hearts were pre-
loaded with [3H]-DOG before 30 min global ischaemia followed
by reperfusion for the times shown. Data are taken from [75].
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perfusion, once maximum recovery of the heart had
been established (post-loading). If reversal of the
MPT occurs during reperfusion, mitochondrial
DOG entrapment following post-loading should be
less than when DOG is present at the start of reper-
fusion (pre-loading). The data of Fig. 5 show that
this is the case. After 40 min ischaemia post-loading
gives about 50% less mitochondrial DOG entrap-
ment than observed with pre-loading. Thus it would
seem that if the insult caused by ischaemia/reperfu-
sion is not too great, mitochondria can undergo a
transient permeability transition, followed by closure
of the pores and entrapment of the DOG. The clo-
sure is presumably brought about by the decrease in
matrix [Ca2] that occurs as calcium is lost from the
mitochondria during the MPT. However, this will
only occur if enough ‘healthy’ mitochondria are re-
maining in the cell to accumulate the released calci-
um and provide su⁄cient ATP to maintain the ionic
homeostasis of the cell. The balance between the
number of ‘closed’ and ‘open’ mitochondria within
any cell will be critical in determining whether a cell
lives or dies. If there are too many ‘open’ mitochon-
dria, they will release more calcium and hydrolyse
more ATP than the ‘closed’ mitochondria can ac-
commodate. In contrast, if there are su⁄cient
‘closed’ mitochondria to meet the cell’s ATP require-
ments and to accumulate released calcium without
undergoing the MPT themselves, the ‘open’ mito-
chondria will close again and the cell will recover.
6. Protection of the heart from reperfusion injury
by inhibitors of the MPT
6.1. Cyclosporin
If the MPT is a critical factor in the development
of reperfusion injury, CsA would be expected to pro-
vide some protection from damage. This has been
observed in isolated cardiac myocytes subjected to
reoxygenation following a period of hypoxia [73]
and in hepatocytes during chemical anoxia and oxi-
dative stress [71,72,78,79]. To test whether such pro-
tection from reperfusion injury by CsA can be ob-
served, hearts were perfused with control medium for
15 min before exposure to di¡erent concentrations of
CsA for 3 min. Isothermic global ischaemia was then
induced for the required period before reperfusion
with medium with or without CsA. Hearts treated
with 0.2 WM CsA recovered signi¢cantly better
than controls after periods of ischaemia of 30 min
or greater, as re£ected in a greater recovery of LVDP
and ATP/ADP ratios, lower AMP levels and EDP
(an indicator of contracture due to low ATP/ADP
and elevated [Ca2]), and a greater recovery of func-
tional mitochondria [16,75,77]. No protective e¡ect
of CsA was observed on the loss of total adenine
nucleotides that occurs as a result of purine degra-
dation during hypoxia. Nor was protection from in-
hibition of respiratory chain function (state 3 sub-
strate oxidation) observed [16,75]. The latter e¡ect
is probably caused by oxygen free radicals, formed
during ischaemia and reperfusion, directly modifying
components of the respiratory chain [16,54,75,77].
Our observations are consistent with CsA exerting
its e¡ects by preventing the MPT, which is down-
stream of changes in total adenine nucleotides and
free radicals. Furthermore, we have demonstrated
that only analogues of CsA that block the MPT in
isolated mitochondria are able to o¡er protection to
the reperfused heart [16,75]. The protective e¡ect of
CsA was highly concentration dependent, showing
an optimal response at 0.2 WM and declining at high-
er concentrations [77]. A similar concentration de-
pendence has been observed for CsA-protection of
isolated cardiac myocytes subjected to reoxygenation
following a period of hypoxia [73]. Massoudy et al.
[80] have also demonstrated a protective e¡ect of
CsA on the working guinea pig heart which was
accompanied by an increase in NO production and
blocked by co-administration of endothelin receptor
antagonists. These authors concluded that CsA pro-
tected the hearts by stimulating endothelin receptor-
mediated NO production which led to a reduction in
oxidative stress, rather than through an e¡ect on the
MPT. However, since oxidative stress strongly acti-
vates the MPT, these two suggestions are not mutu-
ally exclusive.
Direct measurement of the MPT using the DOG
preloading technique failed to detect any decrease in
pore opening in the presence of CsA [16]. If any-
thing, DOG entrapment was enhanced by the pres-
ence of CsA. We attributed this to the nature of CsA
inhibition of the MPT. CsA is known to be ine¡ec-
tive as an inhibitor if [Ca2] is very high, especially
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under conditions of adenine nucleotide depletion and
oxidative stress [22^24,26,27]. Such conditions may
be present during the early phase of reperfusion
and might therefore allow the pore to open even in
the presence of CsA. The functional protection of-
fered by CsA may rather re£ect its ability to accel-
erate subsequent pore closure as glycolysis and re-
maining ‘closed’ mitochondria provide su⁄cient
ATP to restore ion balances and repair other cellular
damage. Paradoxically this may be re£ected in an
increase in DOG entrapment. In order to test this
possibility it will be necessary to determine the extent
of pore opening after post-ischaemic recovery of
hearts using DOG entrapment (post-loading tech-
nique).
6.2. Antioxidants and calcium antagonists
There is an extensive literature to show that anti-
oxidants and free radical scavengers can protect the
ischaemic/reperfused heart from irreversible damage
[54,81]. Whilst there may be many processes within
the cardiac myocyte that are possible targets for the
action of these reagents, prevention of the MPT is
clearly one of them. There is also strong evidence
that mitochondrial calcium overload accompanies re-
perfusion injury [63,82,83], and preventing this with
calcium antagonists [84,85] or ruthenium red, an in-
hibitor of mitochondrial calcium uptake [63,86^90],
also provides protection. Once again, these observa-
tions are consistent with a critical role for the MPT
in reperfusion injury, but they cannot be taken as
proof of such a role [76].
6.3. Low intracellular pH
There is an extensive literature to demonstrate that
low pH (6 7.0) can protect a variety of cells, includ-
ing cardiac myocytes [91^95] and hepatocytes [96^99]
from chemically-induced oxidative stress, re-oxygen-
ation following anoxia or reperfusion following is-
chaemia. These e¡ects can be brought about by using
low extracellular pH or by addition of speci¢c inhib-
itors of the Na/H antiporter such as amiloride
[100^104]. A low intracellular pH (pHi) may have
several means of exerting a protective e¡ect on the
cell, but the profound inhibition of the MPT at pH
6 7.0 [69,70] suggests that prevention of the MPT
pore may be an important one. Support for this
view comes from the observation that during reper-
fusion the MPT pore opens over the same period of
time as the pHi is restored from less than 6.5 to pre-
ischaemic values (s 7.0) [58].
6.4. Pyruvate
It is well documented that pyruvate can protect
hearts against ischaemia/reperfusion and anoxia/re-
oxygenation injury [105^108]. The protective e¡ects
of pyruvate have been attributed to bene¢cial meta-
bolic alterations [105,106,108] and to protection from
free radical production [107,109] since pyruvate acts
as a free radical scavenger [110]. However, an addi-
tional e¡ect of pyruvate might be through inhibition
of the MPT. The free radical scavenging e¡ects of
pyruvate would contribute to this. In addition, as a
good respiratory substrate pyruvate would generate a
high mitochondrial NADH/NAD ratio, preventing
oxidation of protein thiol groups critical for modu-
lation of the MPT voltage sensor, and also a high
membrane potential which would act in concert to
inhibit the MPT [45,46,111]. Furthermore, pyruvate
enters heart cells with a proton by means of the
monocarboxylate transporter (MCT) [55,112]. This
will lead to a decrease in pHi directly, but in addition
pyruvate competes with lactate for transport by the
MCT [55,112] which may lead to a greater intracel-
lular accumulation of lactic acid and further lowering
of pHi. Such an e¡ect would inhibit the MPT still
further. We have demonstrated that the drop in per-
fusate pH of pyruvate-treated hearts on reperfusion
is considerably greater than for control hearts, sug-
gesting that pHi is signi¢cantly lower at the end of
ischaemia and during the reperfusion phase [113].
There is also direct evidence from NMR studies
that pyruvate causes a decrease in pHi in a low-
£ow model of ischaemia [114].
We have used the DOG technique to investigate
whether the protection o¡ered by pyruvate is associ-
ated by inhibition of the MPT [113]. Data summa-
rised in Fig. 5 con¢rm that signi¢cantly less pore
opening does occur on reperfusion when 10 mM pyr-
uvate is present both before ischaemia and during
reperfusion. Under these conditions hearts recover
100% of their LVDP after 40 min ischaemia, com-
pared to only about 50% in the absence of pyruvate.
BBABIO 44666 29-7-98
A.P. Halestrap et al. / Biochimica et Biophysica Acta 1366 (1998) 79^94 89
Furthermore, when the post-loading technique was
used to determine the extent of pore closure after
hearts had recovered their maximum LVDP, DOG
entrapment had returned to pre-ischaemic values.
Thus total functional recovery of the heart was ac-
companied by total reversal of the MPT, whereas
50% recovery was associated with about 50% de-
crease in DOG entrapment and thus 50% reversal
of the MPT. These data are the ¢rst direct evidence
that mitochondrial pore opening can reverse when
hearts damaged by reperfusion recover. We cannot
exclude the possibility that mitochondrial pore open-
ing is secondary to irreversible cell damage, rather
than a primary cause of it. However, as outlined
above, breakdown of the plasma membrane perme-
ability barrier cannot be the cause since if this were
to occur, DOG would be lost from the cells and not
trapped by the mitochondria.
6.5. Propofol
Propofol is an anaesthetic that is frequently used
during cardiac surgery and in post-operative sedation
[115]. There are reports that propofol can act as a
free radical scavenger [116,117] and also that at con-
centrations higher than used clinically, it may inhibit
the permeability transition of isolated mitochondria
[118,119]. One study has suggested that propofol can
attenuate the e¡ects of hydrogen peroxide induced
oxidative stress in the perfused heart [120]. Thus we
have studied the e¡ects of propofol on recovery of
hearts from ischaemia. When added 10 min prior to
ischaemia and during reperfusion at 2 Wg/ml, a con-
centration similar to that employed clinically, signi¢-
cant protection of hearts was observed. Thus recov-
ery of LVDP after 30 min ischaemia (means þ
S.E.M.) increased from 36 þ 8% (n = 10) in control
hearts to 70 þ 11% (n = 8; P6 0.05) in propofol-
treated hearts. This was accompanied by a signi¢cant
decrease in mitochondrial DOG entrapment from
22 þ 2 to 17 þ 1 DOG units (P6 0.05). When added
to isolated heart mitochondria at the same concen-
tration, no inhibition of the MPT was observed.
Thus the protective e¡ect of propofol may not be
through a direct e¡ect on the MPT, but through
other mechanisms such as its free radical scavenging
properties causing a decrease in oxidative stress or
reported inhibitory e¡ects on calcium channels [121,
122] leading to a reduction in calcium overload.
Nevertheless, propofol provides another example of
a reagent whose protection of the heart from reper-
fusion injury is accompanied by a decrease in mito-
chondrial pore opening in vivo.
6.6. Preconditioning
One of the most e¡ective means of protecting is-
chaemic hearts from reperfusion injury is by subject-
ing them to two or three brief (3^5 min) ischaemic
periods with intervening recovery periods before the
prolonged period of ischaemia is initiated. This proc-
ess is called preconditioning and is associated with an
immediate protection which is reduced over a period
of hours, but is followed about 24 h later by a second
window of protection [123,124]. The precise mecha-
nism by which preconditioning exerts its protective
e¡ects is not known, but it seems likely that several
processes are involved. The second window of pro-
tection probably involves stress activated protein kin-
ase pathways [125,126], whilst in the short term pro-
tection mediators such as adenosine, bradykinin,
endothelin 1, opioids, and catecholamines released
during the brief ischaemic periods may cause recep-
tor-mediated activation of protein kinase C [123,127^
129]. Depletion of glycogen during the brief ischae-
mic periods during preconditioning has also been
proposed as an important factor since this will result
in less glycogen breakdown during the prolonged
ischaemic period. This in turn will lead to less lactic
acid production, less Na/H exchange, less accumu-
lation of intracellular Na and hence less increase in
intracellular [Ca2] [130^132]. However, as outlined
above, low pHi is protective and thus this mechanism
will only work if the e¡ects of lower [Ca2] outweigh
those of a smaller decrease in pHi. There is also
evidence for KATP channel activation being involved
in the mechanism of preconditioning, since the e¡ects
are blocked by sulphonylureas, which are potent in-
hibitors of the ATP-K channel [133^135]. Another
mechanism proposed for preconditioning is that the
mitochondrial ATPase inhibitor protein is activated
during the brief ischaemic periods [136,137]. This
would ensure that those mitochondria that have
undergone the MPT break down less of the ATP
generated by glycolysis and by the remaining ‘closed’
mitochondria. Although controversial [137], such a
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mechanism would enable hearts to remain protected
from reperfusion injury even when a signi¢cant num-
ber of mitochondria remained in an ‘open’ state.
Thus it is of interest that, although there are reports
that mitochondrial damage is reduced in precondi-
tioned hearts [138], we have been unable to detect
any decrease in mitochondrial pore opening deter-
mined using the DOG entrapment technique (P.M.
Kerr and A.P. Halestrap, unpublished data).
7. The mitochondrial permeability transition and
apoptosis in the heart
It is now recognised that in the failing heart and
hearts damaged by reperfusion injury some cells
undergo apoptotic cell death as opposed to necrosis.
This is particularly pronounced in areas surrounding
a myocardial infarct, i.e. areas that experience a less
pronounced ischaemic insult than that which leads to
necrosis [139^145]. There is recent evidence that the
MPT may act as the ‘central executioner’ of cells
subjected to a range of insults, such as oxidative
stress, growth factor removal or exposure to cyto-
kines. Indeed, the mitochondria may not determine
only whether cells live or die, but also whether death
occurs by apoptosis or necrosis [146,147]. Thus, in
some cells changes in vi occur during early stages of
apoptosis and can be inhibited by CsA which also
inhibits apoptosis [148,149]. Furthermore, mitochon-
dria are required to induce apoptosis in a cell free
system and appear to do this by release of an apop-
tosis inducing factor which is most probably cyto-
chrome c [150^152]. The anti-apoptotic gene prod-
uct, bcl-2, is associated with the mitochondrial
outer membrane and has been reported to inhibit
the MPT and prevent release of cytochrome c and
consequent caspase activation [153^155].
Attractive though this hypothesis may be, there
are cell types that demonstrate apoptosis without
early changes in vi or inhibition by CsA [153,156^
158]. Nor does CsA protect cell types from all apop-
totic stimuli and may even induce apoptosis under
some circumstances [156,159^161]. However, it does
seem likely that cells experiencing only a modest in-
sult may undergo a transient opening of the MPT
pore which then closes again, enabling ion gradients
and ATP production to be re-established. Under
such conditions, su⁄cient swelling of the outer mem-
brane may occur to release cytochrome c and set in
motion the apoptotic cascade that causes an organ-
ised, non-in£ammatory cell death by apoptosis. The
controlled nature of apoptosis requires that tissue
ATP content is maintained, and where this is not
the case cell death becomes necrotic [162,163]. Such
a situation occurs when a cell experiences a su⁄cient
insult to cause MPT pore opening that is both ex-
tensive and prolonged. Not only is cytochrome c
released, but mitochondria remain uncoupled and
so unable to generate the ATP required for maintain-
ing cellular ionic homeostasis and repairing tissue
damage. Under these conditions damage continues
unabated leading ultimately to rupture of the plasma
membrane and cell death. This uncontrolled necrotic
form of cell death is in£ammatory and further exa-
cerbated as neutrophil invasion leads to yet more
damage. Thus the decision between apoptosis and
necrosis may rest on the extent of the MPT and
can account for the observation that apoptosis and
necrosis both occur in the reperfused heart, with the
least damaged areas showing a preponderance of
apoptosis over necrosis.
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